Navigation Links
HeartWare Presentation At The Barclays Capital 2012 Global Healthcare Conference To Be Webcast
Date:3/7/2012

FRAMINGHAM, Mass. and SYDNEY, March 6, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Barclays Capital 2012 Global Healthcare Conference at 11:15 am EDT on Tuesday, March 13, 2012.  The conference is being held March 13-14, 2012 at the Loews Miami Hotel, Florida.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  A replay of the webcast will be available for 90 days at the site after the presentation.

About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. HeartWare Schedules Fourth Quarter Conference Call and Webcast
2. HeartWare and Dualis MedTech Announce Agreement to Develop Fully Implantable Ventricular Assist System
3. HeartWare to Present at the Oppenheimer 22nd Annual Healthcare Conference
4. HeartWare to Present at the 23rd Annual Piper Jaffray Health Care Conference
5. HeartWare to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
6. HeartWare to Present at the Credit Suisse 2011 Healthcare Conference
7. HeartWare International Announces Planned Departure of Chief Financial Officer
8. HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010
9. HeartWare Announces Presentation of Clinical Data at the 25th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Lisbon
10. HeartWare to Present at The Lazard Capital Markets 3rd Annual Circulatory Assist Device Day
11. HeartWare to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014   LabStyle Innovations Corp ... Management Solution, today announced that it has closed ... shares of preferred stock and warrants.  No placement ... offering expenses, LabStyle expects to secure net proceeds ... LabStyle intends to use the net ...
(Date:9/23/2014)... , September 23, 2014 ... améliorée lors d,une série de démonstrations personnelles   ... dans le domaine de l,analyse de la ... au stand n° 1035 lors de la réunion ... San Diego , en Californie. FDNA ...
(Date:9/23/2014)... , Sept. 23, 2014 Report Details ... showing you trends, R&D and predicted revenues Do ... inhibitors? Now get the latest analysis for those ... results, opportunities and revenue forecasts. Visiongain,s new ... protein kinase inhibition and related technology. There avoid ...
Breaking Medicine Technology:LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 2LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 4LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 5FDNA exposera sa solution Face2Gene intégrée en ligne avec London Medical Databases (LMD) à l'ASHG 2014 2FDNA exposera sa solution Face2Gene intégrée en ligne avec London Medical Databases (LMD) à l'ASHG 2014 3Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 2Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 3Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 4Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 5
... 22, 2011 /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: ... (TCM) products, announced robust record breaking quarterly earnings for ... and $1.8 million in net income, a 219% increase ... the third quarter of 2010. This translates to earnings ...
... HILL, N.C., Nov. 21, 2011  In today,s payer-driven market, ... of a new pharmaceutical product. However, sustaining commercial success ... processes that will increase market share after the product ... of practices to manage the challenges of the pull-through ...
Cached Medicine Technology:China Health Resource Announces Record Breaking 3rd Quarter 2011 Financial Results 2China Health Resource Announces Record Breaking 3rd Quarter 2011 Financial Results 3Managed Care Pull-Through Programs Target Physicians, Boost Market Share 2
(Date:9/23/2014)... (PRWEB) September 23, 2014 "The primary purpose ... control," said an inventor from Sacramento, Ca.. "Call lights are ... or left hanging on the IV pole out of the ... the nurse call device whenever they need it, I created ... effectively position the nurse call device within easy reach. The ...
(Date:9/23/2014)... Davis, and Academia Sinica, the preeminent academic institution ... into a collaborative agreement to develop a unique ... research with opportunities to translate innovative technologies and ... agreement was signed Sept.12 in Taipei by Harris ... and President Chi-Huey Wong of Academia Sinica. The ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 AttorneyOne.com, a ... all the latest information from the FDA on ... 5, that its Private Label Jalapeno Bagels are recalled ... stones. Publix Jalapeno Bagels were sold in ... department. , Taking into consideration the latest developments, ...
(Date:9/23/2014)... Kathleen Doheny HealthDay Reporter ... at very low birth weights, breast milk is more likely ... infection known as cytomegalovirus (CMV), a new study finds. ... infants -- all of whom weighed 3.3 pounds or less ... of CMV infection, to see whether breast milk or transfusions ...
(Date:9/23/2014)... 2014 (HealthDay News) -- Both drinking and getting drunk ... alcohol abuse by high school students, a new study ... high school students who drink, could help expand alcohol-prevention ... drink, to stop them from becoming binge drinkers, the ... of first alcohol use and progression to first heavy ...
Breaking Medicine News(10 mins):Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 2Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 3
... Reactors Could Solve the Isotope Crisis within 24 months ... Nordion, a leading provider of medical isotopes and radiopharmaceuticals, ... Expert Review Panel on Medical Isotope and Technetium-99m (Tc-99m) ... to the shortage of medical radioisotopes is the completion ...
... male and seven female) with hepatic angiomyolipoma, with a ... Of these patients, dynamic contrast CT showed hepatic angiomyolipoma ... of a capsule, and prominent central vessels in six ... without a fat component in four cases with tuberous ...
... , DENVER July 30 Air Methods Corporation ... quarter ended June 30, 2009 after the close of the market on ... for Thursday, August 6, 2009 at 4:15 p.m. Eastern to discuss these ... the call by dialing (877) 883-0656 (domestic) or (706) 643-8826 (international) or ...
... , PLEASANTON, Calif., July 30 TriReme ... second product, a novel coronary dilatation catheter, designed to improve ... near side branches. The product will be marketed under the ... a first-in-class balloon dilatation catheter with a torquable shaft and ...
... centers didn,t increase weight, study found , THURSDAY, July 30 ... else,s home, they,re more likely to be heavier than average ... researchers report in the August issue of Pediatrics ... for in someone else,s home, rather than in their own ...
... WILMINGTON, Del., July 30 AstraZeneca (NYSE: ... a New Drug Application to the U.S. Food and Drug ... European Medicines Agency (EMEA) for an investigational drug, vandetanib 100 ... of advanced non-small cell lung cancer in patients previously treated ...
Cached Medicine News:Health News:MDS Nordion Submits Expression of Interest Proposal to Government of Canada on Medical Isotope and Generator Production 2Health News:MDS Nordion Submits Expression of Interest Proposal to Government of Canada on Medical Isotope and Generator Production 3Health News:TriReme Medical, Inc. Receives CE Marking for Glider(TM) PTCA Dilatation Catheter 2Health News:Infants Cared for in Another Home Become Heavier Toddlers 2Health News:Infants Cared for in Another Home Become Heavier Toddlers 3Health News:AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer 2Health News:AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer 3Health News:AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer 4
... ALLEGRO Topolyzer and T-CAT have been optimized ... vision correction and to interact in perfect ... systems. All necessary treatment and patient parameters ... the ALLEGRETTO WAVE laser systems via diskette, ...
RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is the first and only therapy for patients with keratoconjunctivitis sicca (Dry Eye Disease) whose tear production is presumed to be supressed d...
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
... P.M.® lets you sleep on ... in the morning awake with ... ready to take on the ... comfort and protection, this preservative-free ...
Medicine Products: